Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > Just as expected

<< Previous

Bullboard Posts

Next >>

Comment by Actuarialon Dec 16, 2020 10:59am

156 Views

Post# 32118400

RE:RE:RE:Just as expected

That's totally nosense. With such a low volume, there is neither much profit nor loss you can make or save.

clubhouse19 wrote: That doesn't excuse the folly of managment for what they did. If that is the case, they cud have waited and your plan of holding shares rather than selling waiting to go down to buy more is not very logical either.

Actuarial wrote: We all know what's ahead of the road when we get into 2021. So I don't mind if it goes below 2.00 CAD. Actually, I am waiting to buy more shares as soon as I have another $6000 room in my TFSA.